Clinical Trial Update: Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating adjuvant IP-001 following surgical resection and ablation (or ablation alone) for hepatocellular carcinoma; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IP-001 (IP-001)

Snippet

Sponsor: Robert C. Martin | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING